Spectral AI Names Vincent S. Capone as Chief Executive Officer
Rhea-AI Summary
Spectral AI (Nasdaq: MDAI) appointed Vincent S. Capone as Chief Executive Officer effective February 9, 2026, promoting its CFO and general counsel as the company shifts toward commercialization of its DeepView® non-invasive, AI-driven burn wound assessment device.
The company highlighted its June 2025 FDA submission as a major milestone and said the leadership change will support commercial execution with the chairman remaining as executive chairman.
Positive
- CEO appointment effective Feb 9, 2026
- Internal promotion from CFO and general counsel preserves leadership continuity
- Company transitioning toward commercialization of DeepView System
- FDA submission for DeepView completed in June 2025
Negative
- Commercial launch remains contingent on FDA review; clearance outcome not disclosed
News Market Reaction
On the day this news was published, MDAI gained 0.65%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $309K to the company's valuation, bringing the market cap to $48M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: names like APYX and WOK are up while SRTS and ELUT are down. Only one peer (VNRX, up 7.84%) appears in momentum data, indicating stock-specific factors rather than a broad sector move.
Previous AI Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 02 | Awareness initiative | Positive | -2.9% | Participation in National Burn Awareness Week with ABA partnership and safety outreach. |
| Oct 23 | Growth capital raise | Negative | -0.9% | Equity and warrant financing of $7.6M to support DeepView expansion and readiness. |
| Sep 19 | Industry recognition | Positive | +9.1% | Named to TIME’s World’s Top HealthTech Companies 2025 list for AI wound care. |
| May 29 | Annual meeting results | Neutral | -2.4% | Stockholders approved board slate and auditor with 60.8% of shares represented. |
| May 20 | Clinical award | Positive | +0.7% | Research partners using DeepView won Best Research Project for diabetic foot ulcers work. |
AI-tagged news has produced mixed reactions, with some positive recognition events seeing strong gains while governance and awareness items have sold off.
Over the past year, AI-tagged news for Spectral AI has centered on commercialization and visibility for the DeepView platform. Recognition events, such as inclusion on TIME’s Top HealthTech 2025 list and a partner’s Best Research Project award, coincided with positive moves. In contrast, capital-raising activity on 2025-10-23 and stockholder meeting results on 2025-05-29 saw modest declines. Participation in National Burn Awareness Week on 2026-02-02 also preceded a pullback. Today’s CEO appointment fits into this sequence of governance and commercialization milestones.
Historical Comparison
Past AI-tagged headlines for MDAI have averaged a 0.74% move, with strong upside on high-profile recognition but weaker reactions around governance and awareness items.
AI-tagged history shows a progression from clinical validation and industry awards, to governance approvals and capital raising, and more recently to awareness initiatives as the company advances DeepView toward commercialization.
Regulatory & Risk Context
An effective S-3 resale registration filed on 2025-10-30 covers up to 4,989,502 shares issuable from existing warrants and pre-funded warrants. The company states it will not receive proceeds from stockholder resales, only potential cash from any warrant exercises paid in cash.
Market Pulse Summary
This announcement marks a leadership transition as Spectral AI advances its DeepView burn assessment platform toward commercialization. Recent AI-tagged news has highlighted industry recognition, clinical validation, capital raising, and awareness initiatives. Investors comparing this CEO change to prior milestones may focus on how it supports FDA-related progress, commercialization plans, and the company’s ability to leverage past financing and governance decisions to grow its AI-driven wound care business.
AI-generated analysis. Not financial advice.
DALLAS, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the Company’s Board of Directors has appointed Vincent S. Capone as Chief Executive Officer of the Company, effective February 9, 2026.
The appointment of Mr. Capone, who currently serves as the Company’s Chief Financial Officer and General Counsel, comes as Spectral AI transitions towards commercialization of its proprietary, non-invasive, AI-driven burn wound assessment device – the DeepView® System.
“Vince brings a unique set of leadership skills to his new role, combining a background in law, accounting, finance and operations management supported by a strong vision for the Company’s future,” said Dr. J. Michael DiMaio, Chairman of the Board of Spectral AI. “He has a strong passion for our mission to provide clinicians with a novel technology that re-imagines the current standard of care in burn wound assessment. Vince has played an integral role working with me in leading Spectral AI to this point in our development, and he has earned the respect of our Board, leadership, team members, and partners. His appointment as CEO will help to ensure the evolution of our strategic direction with me as Executive Chairman.”
Mr. Capone has served as Spectral AI’s Chief Financial Officer since February 2024 and as General Counsel since March 2022. He has been a member of the Office of the Chairman since October 2024 which, under the leadership of Dr. DiMaio, has been responsible for day-to-day operational responsibilities and support of the clinical development and commercialization of the DeepView System. Mr. Capone began his career at KPMG LLP before practicing corporate and securities law as a partner with Reed Smith LLP. Prior to joining Spectral AI, he was President of a New York-based private equity fund investing in global life sciences and technology companies.
“I am honored to assume the role of CEO as the Company evolves towards commercialization,” said Mr. Capone. “I am also thankful to work alongside a talented team who drive our success every day. Our FDA submission of the DeepView System in June 2025 marked a major milestone for Spectral AI and a critical step forward to providing this innovative and potentially transformative technology. We are excited to deliver DeepView to the broader healthcare market and advance burn wound care in the U.S. and around the world.”
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is being developed as a predictive diagnostic device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
Investors:
The Equity Group
Devin Sullivan
Managing Director
dsullivan@theequitygroup.com
Conor Rodriguez
Associate
crodriguez@theequitygroup.com
FAQ
Who is the new CEO of Spectral AI (MDAI) and when did the appointment take effect?
What experience does Vincent S. Capone bring to Spectral AI (MDAI) as CEO?
What is the significance of the DeepView System for Spectral AI (MDAI)?
What stage is Spectral AI (MDAI) at with FDA regarding DeepView and when was the submission filed?
How will the leadership change affect Spectral AI's (MDAI) commercialization plans?
Does the appointment of Vincent Capone indicate any immediate financial guidance changes for Spectral AI (MDAI)?
